What is the 13F Pro Quality Score for NTRA?

13F Pro ranks Natera, Inc. (NTRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NTRA's current score at https://13fpro.ai/research/NTRA (free sign-up required for the full ranking).

Where does 13F Pro source NTRA data?

All Natera, Inc. fundamentals and ownership data come directly from SEC EDGAR. Natera, Inc. files with the SEC under CIK 1604821. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NTRA in?

Natera, Inc. (NTRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NTRA research updated on 13F Pro?

NTRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Natera, Inc.(NTRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1604821 NTRA stock profile & AI dashboard →

13F Pro Quality Score

46.4/100

Rank #1,659 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

91.0/100

Profitability

20.7/100

Balance Sheet

14.3/100

Earnings Quality

30.0/100

Free Cash Flow

46.8/100

Institutional Flow

59.4/100

Revenue Scale

65.1/100

Dilution Risk

12.2/100

NTRA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Natera, Inc. (NTRA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NTRA at 46.4/100 on a 32-signal composite quality model, placing it at rank #1,659 of 2,879 stocks — the bottom half of the AI-ranked universe. NTRA scores in the top quartile across revenue growth (91.0). Areas of concern include balance sheet strength (14.3) and profitability (20.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Natera, Inc. reports quarterly revenue of $696.6M, net income of $-85.1M, an operating margin of -13.4%. Top institutional holders of NTRA by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. NTRA trades on the Nasdaq exchange and files with the SEC under CIK 1604821. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NTRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Natera, Inc. directly from SEC EDGAR. Natera, Inc.'s 13F Pro composite quality score has ranged between 8 and 82 since 2021, currently 46.4 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Natera, Inc.

Quirks, history, and lore behind NTRA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in Texas · focused on genetic testing.
2
The Numbers
Annual revenue in the roughly $1 billion range and growing fast, though it has historically operated at a net loss while scaling its lab network.
3
The History
Founded around 2004 and built on technology spun out of Stanford University, it went public on Nasdaq and has steadily expanded beyond its original research roots.
4
The Secret
Its core business is cell-free DNA analysis — fishing tiny fragments of genetic material out of a blood draw to catch problems before symptoms ever appear.
5
The Lore
Its flagship Panorama test screens pregnant women for chromosomal conditions like Down syndrome without a needle anywhere near the baby — a genuine paradigm shift in prenatal care.
6
The Giveaway
The go-to name in non-invasive prenatal testing (NIPT), it also runs oncology liquid biopsy and hereditary cancer panels — making it the closest thing to a genetic early-warning system for the whole human body.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$696.6M

Net Income

Q1 2026

$-85.1M

Free Cash Flow

Q1 2026

$18.0M

Operating Margin

Q1 2026

-13.4%

D/E Ratio

Q1 2026

0.05

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+56.7% YoY

$1.70BFY 2024

FY21 $625.5MFY22 $820.2MFY23 $1.08BFY24 $1.70B

Net Income

+56.2% YoY

$-190.4MFY 2024

FY21 $-471.7MFY22 $-547.8MFY23 $-434.8MFY24 $-190.4M

Operating Income

+50.2% YoY

$-222.3MFY 2024

FY21 $-468.2MFY22 $-541.0MFY23 $-446.2MFY24 $-222.3M

EPS (Diluted)

+59.5% YoY

$-1.53FY 2024

FY21 $-5.21FY22 $-5.57FY23 $-3.78FY24 $-1.53

Total Assets

+15.2% YoY

$1.66BFY 2024

FY21 $1.24BFY22 $1.39BFY23 $1.44BFY24 $1.66B

Total Debt

-77.9% YoY

$80.4MFY 2024

FY21 $330.4MFY22 $362.0MFY23 $363.3MFY24 $80.4M

Op. Cash Flow

+154.9% YoY

$135.7MFY 2024

FY21 $-335.2MFY22 $-431.5MFY23 $-247.0MFY24 $135.7M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$1.70B +56.7%	$1.08B +32.0%	$820.2M +31.1%	$625.5M +60.0%	$391.0M +29.3%	$302.3M
Net Income	$-190.4M +56.2%	$-434.8M +20.6%	$-547.8M -16.1%	$-471.7M -105.3%	$-229.7M -84.0%	$-124.8M
Operating Income	$-222.3M +50.2%	$-446.2M +17.5%	$-541.0M -15.6%	$-468.2M -116.5%	$-216.3M -86.0%	$-116.3M
EPS (Diluted)	$-1.53 +59.5%	$-3.78 +32.1%	$-5.57 -6.9%	$-5.21 -83.5%	$-2.84 -58.7%	$-1.79
Total Assets	$1.66B +15.2%	$1.44B +3.4%	$1.39B +12.8%	$1.24B +32.6%	$932.2M +60.0%	$582.7M
Total Debt	$80.4M -77.9%	$363.3M +0.4%	$362.0M +9.5%	$330.4M +560.2%	$50.1M -0.1%	$50.1M
Operating Cash Flow	$135.7M +154.9%	$-247.0M +42.8%	$-431.5M -28.7%	$-335.2M -83.7%	$-182.5M -187.7%	$-63.4M

AI Insight: NTRA Financial Trends

Revenue acceleration to $697M masks deepening operating losses and swinging profitability; Q4 2025 was an anomaly, not a trend.

• Revenue grew 69% from Q2 2024 ($413M) to Q1 2026 ($697M), accelerating quarterly run-rate despite persistent operating losses.

• Operating income deteriorated from -$44M in Q2 2024 to -$94M in Q1 2026; Q4 2025's -$23M was a one-quarter exception.

• Net income swung from -$37M loss in Q2 2024 to $47M profit in Q4 2025, then back to -$85M loss in Q1 2026—volatile.

• Equity expanded 112% from $837M (Q2 2024) to $1,774M (Q1 2026); debt held flat at $80M except Q4 2024–Q1 2025 spike.

⚠ Operating margins remain deeply negative despite strong revenue growth; Q1 2026 op margin at -13.5%, nearly as bad as peak losses.

⚠ Q4 2025 profitability ($47M net income) appears isolated; Q1 2026 reverted to -$85M. Path to sustained profitability unclear.

⚠ Operating cash flow volatile (range $38M–$74M) despite growing revenue; inconsistency hints at working-capital or collection pressure.

AI Insight: NTRA Ratio Trends

Natera swung to Q4 2025 profitability but has deteriorated sharply into Q1 2026, with OpMargin falling to -13.4% and ROIC collapsing to -20.2%.

• Q4 2025 marked dramatic inflection: OpMargin improved to -3.4%, NPM turned positive at 7.1%, ROE reached 11.0%.

• Q1 2026 reversal severe: OpMargin declined to -13.4%, NPM dropped to -12.2%, ROE fell to -19.2%.

• ROIC deteriorated from -5.1% in Q4 2025 to -20.2% in Q1 2026; leverage stable at 0.05 D/E.

⚠ Q4 2025 profitability proved unsustainable—one quarter of positive earnings erased in Q1 2026 reversion.

⚠ TTM OpMargin at -13.0% masks wide volatility; Q2 2025 reached -20.2% low, suggesting operational instability.

Get alerted when NTRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Natera, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NTRA

BlackRock, Inc.
$2.1B10,677,338 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2B6,008,496 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.1B5,644,695 sh
WELLINGTON MANAGEMENT GROUP LLP
$953.7M4,768,593 sh
STATE STREET CORP
$683.5M3,417,472 sh
FARALLON CAPITAL MANAGEMENT LLC
$641.4M3,207,366 sh
GEODE CAPITAL MANAGEMENT, LLC
$553.8M2,775,928 sh
FMR LLC
$510.8M2,554,254 sh
COATUE MANAGEMENT LLC
$508.3M2,541,842 sh
Castle Hook Partners LP
$505.9M2,529,810 sh

Fund	Value	Shares
BlackRock, Inc.	$2.1B	10,677,338
VANGUARD CAPITAL MANAGEMENT LLC	$1.2B	6,008,496
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.1B	5,644,695
WELLINGTON MANAGEMENT GROUP LLP	$953.7M	4,768,593
STATE STREET CORP	$683.5M	3,417,472
FARALLON CAPITAL MANAGEMENT LLC	$641.4M	3,207,366
GEODE CAPITAL MANAGEMENT, LLC	$553.8M	2,775,928
FMR LLC	$510.8M	2,554,254
COATUE MANAGEMENT LLC	$508.3M	2,541,842
Castle Hook Partners LP	$505.9M	2,529,810

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NTRA on your watchlist

Track score changes the day Natera, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NTRA a good stock to buy?

13F Pro's AI-powered analysis of Natera, Inc. (NTRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NTRA are available on the NTRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NTRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NTRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Natera, Inc.'s investment landscape.